吡罗昔康原料晶型对片剂溶出度的影响研究

目的：研究吡罗昔康原料及其在片剂中的晶型特征，并探讨不同晶型对吡罗昔康原料、片剂溶出度的影响。方法：通过差示扫描量热分析（DSC）、傅里叶红外光谱（FTIR）、粉末X 射线衍射谱（PXRD）测定吡罗昔康原料的晶型；通过近红外光谱（NIR）使用相关系数模型快速筛查吡罗昔康片的原料晶型；使用光纤溶出仪测定不同晶型原料的固有溶出速率及不同晶型原料片剂的溶出度。结果：目前市场上吡罗昔康原料主要存在2 种晶型；不同晶型的吡罗昔康原料固有溶出速率存在差异，不同原料晶型片剂溶出度亦有一定差异。结论：吡罗昔康P Ⅱ晶型与P Ⅰ晶型相比，溶出行为更优，晶型的测定为吡罗昔康的质量控制提供了科学依据。

Objective: To investigate the polymorphic forms of piroxicam and its influence of polymorphism on dissolution proflie in tablets. Methods: The crystal forms of piroxicam were measured and analyzed by differential scanning calorimeter(DSC),Fourier transform infrared spectroscopy(FTIR)and X-ray powder diffractometer (PXRD);the correlation coefficient model was applied for rapid screening of the crystal form of API in piroxicam tablets by near-infrared spectroscopy(NIR);the intrinsic dissolution rates of different crystal forms of piroxicam as well as the dissolution rates of piroxicam tablets were investigated. Results: Two different crystal forms of piroxicam were observed;differences of intrinsic dissolution rate and dissolution rate of tablets between various polymorphic forms were confirmed . Conclusion: Piroxicam of polymorphic form P Ⅱ has better solubility compared with the from P Ⅰ,and crystal form investigation provide a scientific evidence for the specification setting of piroxicam and dosage forms.

[1] 徐积恩,刘松林. 昔康(Oxicam)类非甾体消炎镇痛药的现状和 动向[J]. 药学进展,1992,16(1):20 XU JN,LIU SL. Situation and trends of non-steroidal antiinflammatory analgesicof meloxicam(Oxicam)[J]. Prog Pharm Sci, 1992,16(1):20
[2] 国家食品药品监督管理局修订吡罗昔康全身给药制剂说明书[J]. 中国药事,2009,23(3):213 Revised instructions for systematic adminstration of piroxicamloy the stute food and drug udminstration. [J]. Chin Pharm Aff,2009, 23(3):213
[3] 中国药典2015 年版. 二部[S]. 2015:469 ChP 2015. Vol Ⅱ[S]. 2015:469
[4] BP 2015. Vol Ⅱ[S]. 2015:603
[5] JP 16[S]. 2011:1261
[6] 刘巍. 固体核磁技术在药物多晶型研究中的作用[D]. 兰州:兰 州大学化学化工学院,2011 LIU W. Structural Studies of Polymorphs of Pharmaceutical Compound Using Solid-State NMR Spectroscopy[D]. Lanzhou: College of Chemistry and Chemical Engineering,Lanzhou University,2011
[7] 赵会英,苏德森,胡愈,等. 吡罗昔康多晶型的制备及其热稳定性[J]. 沈阳药科大学学报,2000,17(2):101,113 ZHAO HY,SU DS,HU Y,et al. Preparation and thermal stability of the crystalline form of piroxicam[J]. J Shenyang Pharm Univ, 2000,17(2):101,113
[8] 付金广. 吡罗昔康工艺的改进[J]. 山东化工,2013,42(9):19 FU JG. Improvement of piroxicam synthesis[J].Shandong Chem Ind,2013,42(9):19
[9] 陈桂良,李君婵,彭兴盛,等. 药物晶型及其质量控制[J]. 药物分 析杂志,2012,32(8):1503 CHEN GL,LI JC,PENG XS,et al. Drug polymorphism and its quality control[J]. Chin J Pharm Anal,2012,32(8):1503
[10] 陈华,赵文,毛睿,等. 2 种晶型利福平制剂之间溶出曲线的差异[J]. 药物分析杂志,2013,33(5):881 CHEN H,ZHAO W,MAO R,et al. Differences of dissolution profiles between two crystalline types of fixed dose combinations of rifampin[J]. Chin J Pharm Anal,2013,33(5):881
[11] 王建,曾红霞,陈悦. 罗红霉素晶型分析与溶解速率、溶出度的关 系[J]. 中国现代应用药学,2013,30(10):1094 WANG J,ZENG HX,CHEN Y. Relationship of roxithromycin crystal types,dissolution rates and dissolution[J]. Chin J Mod Appl Pharm,2013,30(10):1094
[12] 郝甜媛,刘欢,陈常青. 晶型转化对药物稳定性的影响研究进展[J]. 现代药物与临床,2013,28(3):457 HAO TY,LIU H,CHEN CQ. Advances in study on influence of crystal transformation on drug stability[J]. Chin J Mod Appl Pharm,2013,28(3):457
[13] 仿制药晶型研究的技术指导原则[EB/OL]. [2009-6] [2015-8-16]. http://www.cde.org.cn/guide.do?method=showGuide&id=210 Technical Guidelines for the Study of Generic Drug Crystal Forms[EB/OL].2009-6[2015-8-16].http://www.cde.org.cn/guide.do?method=showGuide&id=210
[14] 中国药典2015 年版. 四部[S].2015:371 ChP 2015.Vol Ⅳ[S].2015:371
[15] USP 34-NF 29[S].2011:609
[16] 普通口服固体制剂溶出度试验技术指导原则[EB/OL].[2015-2-5] [2015-8-15] Technical Guidelines for Dissolution Testing of Common Oral Solid Preparations[EB/OL].2015-2-5[2015-8-15].http://www.cde.org.cn/zdyz.do?method=largePage&id=236